Inactive Instrument

Highlights Roche Holding AG Swiss Exchange

Stocks

ROG

CH0012032048

Pharmaceuticals

Delayed Swiss Exchange Other stock markets 11:31:03 2026-07-08 am EDT			5-day change	1st Jan Change
334.90 ^CHF	-1.35%		+2.01%	+2.04%

Jul. 09	Roche's Tuberculosis Test Receives CE Mark	MT
Jul. 08	ABB Robotics Partners with Roche Diagnostics	MT

Highlights

Jul. 09	Roche's Tuberculosis Test Receives CE Mark	MT
Jul. 08	ABB Robotics Partners with Roche Diagnostics	MT
Jul. 07	Roche Presents New Data in Alzheimer?S Disease Portfolio At Aaic 2026	CI
Jul. 02	Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer	CI
Jun. 30	Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease	CI
Jun. 30	Roche Receives US Priority Review Status for Thyroid Eye Disease Treatment	MT
Jun. 29	Excalipoint Therapeutics And Roches Announce Clinical Trial Collaboration To Evaluate EXP011 In DLL3-Expressing Solid Tumors	CI
Jun. 29	Roche Announces Launch Of AXELIOS 1 Sequencing Platform	CI
Jun. 29	Switzerland's Roche Introduces New Sequencing Platform	MT
Jun. 24	Roche Holding AG Announces FDA Grants Priority Review Status to its Atezolizumab for Treatment of Certain Type of Stage III Colorectal Cancer	CI
Jun. 18	Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma	CI
Jun. 18	Roche Wins US FDA Nod for Lymphoma Drug Combo	MT
Jun. 17	FDA approves first generic version of Roche's flu drug	RE
Jun. 12	Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer	CI
Jun. 11	Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer	CI
Jun. 11	Roche's Tecentriq, Chemotherapy Combo Gets US FDA Priority Review for Colon Cancer	MT
Jun. 11	Roche Announces IVDR Approval For VENTANA MMR RxDx Panel Companion Diagnostic Across Multiple Cancer Types And Therapies	CI
Jun. 08	Roche Holding AG And Nurix Therapeutics, Inc. Announce Global Collaboration To Co-Develop And Co-Commercialise Potential Best-In-Class BTK Degrader Bexobrutideg Across Malignant Haematology, Immunology And Neurology	CI
Jun. 08	Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics	RE
Jun. 08	Roche enters $2 billion cancer drug agreement with Nurix Therapeutics	RE
Jun. 08	Roche, Nurix Therapeutics to Develop, Commercialize BTK Degrader Bexobrutideg	MT
Jun. 05	Zealand touts promising tolerability data for obesity drug in mid-stage study	RE
Jun. 02	Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi in Combination with Palbociclib and Fulvestrant	CI
Jun. 02	Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer	CI
Jun. 02	Roche Wins US FDA's Priority Review for Breast Cancer Treatment Giredestrant	MT